Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Stock Price Down 6.6% – Should You Sell?

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM – Get Free Report) shares traded down 6.6% on Wednesday. The stock traded as low as C$0.28 and last traded at C$0.28. 4,800 shares changed hands during trading, an increase of 68% from the average session volume of 2,858 shares. The stock had previously closed at C$0.30.

Zomedica Pharmaceuticals Corp. (ZOM.V) Stock Down 6.6%

The company has a debt-to-equity ratio of 4.91, a current ratio of 15.31 and a quick ratio of 15.24. The stock’s fifty day simple moving average is C$0.29 and its 200-day simple moving average is C$0.28. The stock has a market cap of C$36.73 million and a P/E ratio of -2.61.

Zomedica Pharmaceuticals Corp. (ZOM.V) Company Profile

(Get Free Report)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination.

See Also

• Five stocks we like better than Zomedica Pharmaceuticals Corp. (ZOM.V)
• Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
• O’Reilly Automotive’s Stock Slump Hides a Stronger Business
• McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
• Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test

Receive News & Ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and related companies with MarketBeat.com's FREE daily email newsletter.